Evidence map›Paper›PMID 39420015›Full record

ArticleNature communications2024

Single molecule tracking based drug screening.

Daisuke Watanabe, Michio Hiroshima, Masato Yasui, Masahiro Ueda

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. ACS central science · 2026
    Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Daisuke WatanabeLaboratory of Single Molecule Biology, Graduate School of Frontier Biosciences, Osaka University, Suita, Osaka, Japan.ORCID 0009-0007-3330-6582
Michio HiroshimaLaboratory of Single Molecule Biology, Graduate School of Frontier Biosciences, Osaka University, Suita, Osaka, Japan. m_hiroshima.fbs@osaka-u.ac.jp.ORCID 0009-0000-0613-6724
Masato YasuiZIDO Corporation, Toyonaka, Osaka, Japan.ORCID 0009-0000-9481-8732
Masahiro UedaLaboratory of Single Molecule Biology, Graduate School of Frontier Biosciences, Osaka University, Suita, Osaka, Japan. ueda.masahiro.fbs@osaka-u.ac.jp.ORCID 0000-0002-9354-3404

Funding

Japan Agency for Medical Research and Development (AMED) JP23ym0126815MEXT | Japan Society for the Promotion of Science (JSPS) 18H05414MEXT | JST | Core Research for Evolutional Science and Technology (CREST) JPMJCR21E1Ministry of Education, Culture, Sports, Science and Technology (MEXT) 18H01839Ministry of Education, Culture, Sports, Science and Technology (MEXT) 22H02593
6 · The paper itself

Abstract

The single-molecule tracking of transmembrane receptors in living cells has provided significant insights into signaling mechanisms, such as mobility and clustering upon their activation/inactivation, making it a potential screening method for drug discovery. Here we show that single-molecule tracking-based screening can be used to explore compounds both detectable and undetectable by conventional methods for disease-related receptors. Using an automated system for a fast large-scale single-molecule analysis, we screen for epidermal growth factor receptor (EGFR) from 1134 of FDA approved drugs. The 18 hit compounds include all EGFR-targeted tyrosine kinase inhibitors (TKIs) in the library that suppress any phosphorylation-dependent mobility shift of EGFR, proving the concept of this approach. The remaining hit compounds are not reported as EGFR-targeted drugs and do not inhibit EGF-induced EGFR phosphorylation. These non-TKI compounds affect the mobility and/or clustering of EGFR without EGF and induce EGFR internalization, to impede EGFR-dependent cell growth. Thus, single-molecule tracking provides an alternative modality for discovering therapeutics on various receptor functions with previously untargeted mechanisms.

Indexed as

ErbB ReceptorsProtein Kinase InhibitorsSingle Molecule ImagingCell Line, TumorCell ProliferationDrug DiscoveryDrug Evaluation, PreclinicalEpidermal Growth FactorHumansPhosphorylationSignal TransductionEGFR protein, humanEpidermal Growth FactorErbB ReceptorsProtein Kinase Inhibitors

Identifiers

PMID39420015
PMCPMC11486946

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.